Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP1 | Q9P0U3 | 3/20 | 0.47 |
| ▸ | CCKBR | P32239 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 4/20 | 0.40 |
| ▸ | BRD2 | P25440 | 4/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545317 | 1.00 | SENP1 (0.47) | SENP1CCKBRCYP3A4MAPTTSHR | |
| SCHEMBL7546386 | 0.92 | SENP1 (0.48) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL7546390 | 0.92 | SENP1 (0.48) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL7552364 | 0.90 | SENP1 (0.46) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL7552736 | 0.90 | SENP1 (0.46) | SENP1CCKBRMAPTBRD4BRD2 | |
| SCHEMBL7575534 | 0.90 | SENP1 (0.46) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL7575526 | 0.90 | SENP1 (0.46) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL7552727 | 0.90 | SENP1 (0.46) | SENP1CCKBRMAPTBRD4BRD2 | |
| SCHEMBL7549947 | 0.88 | SENP1 (0.45) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL7549944 | 0.88 | SENP1 (0.45) | SENP1CCKBRBRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | SENP1 3511/4885CCKBR 2/4885CYP3A4 318/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | SENP1 3511/4885CCKBR 2/4885CYP3A4 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.